Accueil>>Signaling Pathways>> Chromatin/Epigenetics>> Epigenetic Reader Domain>>FHD-286

FHD-286

Catalog No.GC64821

Le FHD-286 est un inhibiteur de BRG1/BRM ATPase pour le traitement des troubles liés au BAF tels que la leucémie myéloÏde aiguë.

Products are for research use only. Not for human use. We do not sell to patients.

FHD-286 Chemical Structure

Cas No.: 2671128-05-3

Taille Prix Stock Qté
5 mg
405,00 $US
En stock
10 mg
630,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

FHD-286 is a BRG1/BRM ATPase inhibitor for the treatment of BAF-related disorders such as acute myeloid leukemia.

[1]. Centore, Richard C. et al. Preparation of BRG1/BRM inhibitors for treating cancer. US20220079940 A1.

Avis

Review for FHD-286

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for FHD-286

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.